Chronic Obstructive Pulmonary Disease, Lung Cancer, Tabagism
Conditions
Keywords
Screening, Tabagism, Chronic Obstructive Pulmonary Disease, Cancer, Lung
Brief summary
Smokers do not know the symptoms of cancer and wait on average 5 months with symptoms before consulting. 80% of lung cancers are diagnosed at too late and incurable stage. Systematic CT screening of smokers is under evaluation and currently not supported because expensive and little used in real life (in the US 1.8% of smokers after 7 years of establishment in the USA). An English study showed an increase in the number of operable stage cancers of 3% among smokers by calling them on a trailing cough by a simple poster campaign (You smoke, you cough for more than 3 weeks, consult). Regarding COPD, it is linked to tobacco in 85% of cases, affects 3.5 million French and is in 2013 the 4th leading cause of death in France. The evolution of COPD is marked by exacerbations, period of acute aggravation of symptoms, responsible for the deterioration of the quality of life or even hospitalization or death. COPD remains a silent killer responsible, according to this same summary review, of 16,500 deaths per year in France. Dr DENIS has developed a web application that has shown a 7-month survival benefit by early detection of lung cancer relapses based on the reporting of patient symptoms analyzed by a validated algorithm in 300 patients and 1 randomized trial. The Applitabac app takes this concept of symptom self-assessment by patients. By multiplying the number of symptoms analyzed compared to the English study, Applitabac should be able to increase the sensitivity of this early detection of COPD and increase the number of operable bronchial cancers and increase the chances of survival of patients.
Interventions
DEVICEApplitabac
Smartphone application in screening on tabagism complications
Sponsors
Le Mans Town Hall (72)
Department of Sarthe (72)
Weprom
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age \>= 18 years old * Applitabac user who has received a notification directing him to his doctor * Smoker or former smoker (current smoking cessation or ≤ 5 years) * Patient informed of the use of his data and not opposing it
Exclusion criteria
* Presence of another evolutionary neoplasia in the past 2 years * Patient who did not use the Applitabac app
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients fit for surgery for a symptomatic stage I-II lung cancer during the 12 weeks after the web-application rollout | 12 weeks | Proportion of patients fit for surgery for a symptomatic stage I-II lung cancer during the 12 weeks after the web-application rollout |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of diagnosed lung cancers, by stage and total first and second year of follow-up | first and second year of follow-up | Proportion of diagnosed lung cancers, by stage and total first and second year of follow-up |
| Stage of lung cancer surgery with Applitabac first and second year of follow-up | first and second year of follow-up | Stage of lung cancer surgery with Applitabac first and second year of follow-up |
| Histological stage of diagnosed lung cancer | second year of follow-up | Histological stage of diagnosed lung cancer |
| Stages of other cancers of Applitabac users diagnosed with Applitabac in the first and second year of follow-up | first and second year of follow-up | Stages of other cancers of Applitabac users diagnosed with Applitabac in the first and second year of follow-up |
| Proportion of other cancers of Applitabac users diagnosed with Applitabac in the first and second year of follow-up | first and second year of follow-up | Proportion of other cancers of Applitabac users diagnosed with Applitabac in the first and second year of follow-up |
| Proportion of Applitabac-induced thoracic interventions without a cancer diagnosis first and second year of follow-up | first and second year of follow-up | Proportion of Applitabac-induced thoracic interventions without a cancer diagnosis first and second year of follow-up |
| Proportion of patients operated on for lung cancer during the first and second year of follow-up in comparaison of 2017/2018 | first and second year of follow-up | Proportion of patients operated on for lung cancer during the first and second year of follow-up in comparaison of 2017/2018 |
| Stage of diagnosis of COPD detected by the application (GOLD classification : VEMS) | second year of follow-up | Stage of diagnosis of COPD detected by the application (GOLD classification : VEMS) |
| Distribution of the stages of operated lung cancer, the two years preceding the implementation of Applitabac over similar periods | Two years before use of Applitabac | Distribution of the stages of operated lung cancer, the two years preceding the implementation of Applitabac over similar periods |
| Compare the distribution of the stages of operated patients (app vs. not app) | second year of follow-up | Compare the distribution of the stages of operated patients (app vs. not app) |
| Comparison of the stage distribution of patients operated before / after implementation of the application (via Epithor data base) | second year of follow-up | Comparison of the stage distribution of patients operated before / after implementation of the application (via Epithor data base) |
| Number of users who want to quit after first use | 30 minutes after application implementation | Number of users who want to quit after first use |
| Proportion of patients with another pathology detected by Applitabac in the first and second year of follow-up | first and second year of follow-up | Proportion of patients with another pathology detected by Applitabac in the first and second year of follow-up |
Countries
France
Outcome results
None listed